Description
CD161, also known as natural killer (NK) cell receptor P1A (NKR-P1A), is a type II transmembrane protein that is encoded by the Klrb1a gene in mice.1 It is composed of an N-terminal cytoplasmic domain, a transmembrane domain, a stalk region, and an extracellular region that contains the C-type lectin-like domain and is expressed in NK cells and T cells.1,2 NKR-P1A is an inhibitory receptor in humans, which is stimulated by its ligand lectin-like transcript 1 (LLT-1) and signals through the PI3K/Akt/ERK pathway, whereas Nrk-p1a is an activating receptor in mice, which signals through the immunoreceptor tyrosine-based activation motifs (ITAMs) of adaptor proteins.1 Monoclonal antibodies targeting NKR-P1A increase T cell-induced cytotoxicity and decrease programmed cell death protein 1 (PD-1) levels in glioblastoma cells and knockout of KLRB1 increases survival in a humanized mouse model of glioblastoma.3 Levels of NKR-P1A are increased in CD4+ and CD8+ T cells in patients with advanced stage osteoarthritis.4 Cayman’s NKR-P1A/CD161 Extracellular Domain (mouse, recombinant) protein consists of 180 amino acids and has a calculated molecular weight of 21 kDa. By SDS-PAGE, under reducing conditions, the apparent molecular mass of the protein is 30-35 kDa due to glycosylation.WARNING This product is not for human or veterinary use.
